Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.
Bradley Monk, MD, FACOG, FACS, professor at the University of Arizona and Creighton University in Phoenix and clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.
Transcript
In your experience, who are the patients who fare best with PARP inhibitors for ovarian cancer?
The first randomized trials to show efficacy of PARP inhibitors were these 3 maintenance treatments in recurrent ovarian cancer, and olaparib has 2 studies, Study 19 and SOLO2; niraparib of has one, NOVA; and then rucaparib has 1, ARIEL3. And so you can now use PARP inhibitors in treatment in recurrent ovarian cancer based on level 1 randomized trial data, if the patient responds to platinum, across all biomarker subgroups, because response to platinum in the recurrent setting is the biomarker. So again, if you treat a patient in platinum-sensitive relapse with carboplatin-paclitaxel, or carboplatin-liposomal doxorubicin, or even carboplatin-gemcitabine, if she responds, you can keep her in response with either olaparib, rucaparib, or niraparib without sort of ruining the patient experience. All of those studies have no decrement in patient reported outcomes, and no new safety signals identified.
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Most Patients With Mucinous Ovarian Cancer Don't Need Perioperative GI Endoscopy
April 12th 2024A new study suggests routine gastrointestinal (GI) endoscopy is not needed for most patients with mucinous ovarian cancer in the perioperative setting due to a lack of statistically significant overall survival benefits.
Read More
Model Including Diffusion-Weighted MRI More Accurately Predicts Ovarian Cancer Resectability
April 4th 2024A recent study suggests a modified model incorporating diffusion-weighted MRI can more accurately predict ovarian cancer primary debulking surgery outcomes compared with the standard, widely used Memorial Sloan Kettering Cancer Center risk model.
Read More
Patients Treated With Mirvetuximab Soravtansine vs Chemotherapy Report Better HRQOL
March 29th 2024An abstract presented at the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer explored patient-reported health-related quality of life (HRQOL) among patients treated with mirvetuximab soravtansine compared with standard chemotherapy.
Read More
Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer
March 22nd 2024Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.
Read More